🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Me and Avik Roy at Simmaron Research are excited to share our newest perspective article published in Biomolecules on BH4 metabolism in ME/CFS patients as it relates to OI pathogenesis #ME/CFS, #POTs #LongCovid mdpi.com/2218-273X/15/1…

Excited to see our recent disease relevant model of PEM was highlighted in IASP “Papers of the Week” iasp-pain.org/publications/p… Avik Roy Simmaron Research #PEM #ME #LongCovid

In our #ME mouse model publication, we show that chronic mTOR activation disrupts autophagy function, leading to #PEM and the production of IL-6 and RANTES via STAT3 phosphorylation! #MECFS Read the publication: rdcu.be/d5yaB

Had the honor of presenting the initial patient-reported outcomes of the collaborative rapamycin study led by Simmaron Research at ACP #IM2025 today! Had an amazing time talking with clinicians from all over the country about advancing the knowledge and care of #MECFS

So psyched to have Stephanie Grach MD MS present some early data on Simmaron Research rapamycin study. Without clinicians like Dr Grach, and our other clinical experts me and Avik Roy would have no patients to study. Manuscript is forthcoming! #MECFS #longcovid

Inactivation of ATG13 stimulates chronic demyelinating pathologies in muscle-serving nerves and spinal cord - PubMed pubmed.ncbi.nlm.nih.gov/39777574/

Elevated ATG13 in serum of patients with ME/CFS stimulates oxidative stress response in microglial cells via activation of receptor for advanced glycation end products (RAGE) - PubMed pubmed.ncbi.nlm.nih.gov/35487443/

🚨 Big news! Simmaron Research wins our latest Solve #MECFS Catalyst Award! We’re proud to provide funding for the Low-Dose Rapamycin trial. Congrats to Gunnar Gottschalk Avik Roy & the whole Simmaron Research team! 💡 Learn more:ow.ly/WSsW50WavSb